Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC

This study is a single arm, open-label, intravenous infusion of Anti- Epidermal growth factor receptor (EGFR) Chimeric Antigen Receptor (CAR) T cells modified by C-X-C Chemokine receptor type 5 (CXCR 5) in patients with advanced adult non-small cell lung cancer (NSCLC).

Trial Details

NCT ID
NCT05060796
Phase
EARLY_PHASE1
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells
Locations (sample)
  • Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • All subjects or legal guardians must sign the informed consent form approved by the ethics committee in writing before starting any screening proce…
  • 18 Years to 75 Years, Histologically or cytologically confirmed Routine treatment of patients with advanced non-small cell lung cancer(Including TK…
  • After the signature of the informed consent and prior to the collection of a single nuclear cell, the immuno- histochemical test must determine tha…
  • Pathological results suggest that CXCL13 factor positive rate ≥ 10 %;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →